SurModics (SRDX) Set to Announce Quarterly Earnings on Friday

SurModics (NASDAQ:SRDX) is set to announce its earnings results before the market opens on Friday, November 9th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.

SurModics (NASDAQ:SRDX) last issued its quarterly earnings data on Monday, August 6th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.51. The firm had revenue of $22.23 million during the quarter, compared to analysts’ expectations of $19.81 million. SurModics had a positive return on equity of 7.53% and a negative net margin of 2.94%. On average, analysts expect SurModics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of NASDAQ SRDX opened at $64.69 on Wednesday. The firm has a market cap of $868.12 million, a P/E ratio of 126.84, a P/E/G ratio of 216.73 and a beta of 0.90. SurModics has a 1-year low of $25.00 and a 1-year high of $82.35.

In other SurModics news, VP Gregg S. Sutton sold 14,824 shares of the stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $74.14, for a total value of $1,099,051.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Susan E. Knight sold 6,000 shares of the stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $72.93, for a total value of $437,580.00. Following the completion of the sale, the director now owns 19,728 shares of the company’s stock, valued at $1,438,763.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,824 shares of company stock valued at $1,987,201. 7.70% of the stock is currently owned by company insiders.

A number of equities research analysts recently weighed in on SRDX shares. BidaskClub cut SurModics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Needham & Company LLC restated a “buy” rating and set a $74.00 price objective on shares of SurModics in a research note on Monday, August 6th. Lake Street Capital upped their price objective on SurModics to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Finally, Barrington Research upped their price objective on SurModics to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 7th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. SurModics currently has an average rating of “Buy” and a consensus price target of $71.75.

TRADEMARK VIOLATION NOTICE: “SurModics (SRDX) Set to Announce Quarterly Earnings on Friday” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/07/surmodics-srdx-set-to-announce-quarterly-earnings-on-friday.html.

SurModics Company Profile

Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

See Also: Stock Symbols Definition, Examples, Lookup

Earnings History for SurModics (NASDAQ:SRDX)

Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply